Gilead Sciences (GILD) Tops Q1 EPS by 13c, Beats on Revenue; Offers FY26 Guidance
Tweet
Share
E-mail
Get Alerts GILD Hot Sheet
Price: $123.76 -1.35%
Revenue Growth %: +4.4%
Financial Fact:
Cost of goods sold: 1.13B
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: +4.4%
Financial Fact:
Cost of goods sold: 1.13B
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Gilead Sciences (NASDAQ: GILD) reported Q1 EPS of $2.03, $0.13 better than the analyst estimate of $1.90. Revenue for the quarter came in at $7 billion versus the consensus estimate of $6.91 billion.
GUIDANCE:
Gilead Sciences sees FY2026 EPS of ($1.05)-($0.65), versus the consensus of $8.65. Gilead Sciences sees FY2026 revenue of $30-30.4 billion, versus the consensus of $30.2 billion.
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kalshi in early talks for IPO - The Information
- Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
- Grizzly Discoveries closes private placement raising $349,044
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
